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Abstract
Biomarkers are emerging research filed in the past decade. Even though numer-
ous biomarkers were reported, the efficiency of cancer therapy remains low. So the
question emerges as to how much can we trust the current biomarkers on cancer
therapy? In this upcoming chapter, we would like to illustrate the outcomes of
classical cancer therapies on advanced pancreatic cancer disclosed successful,
neutral and failed in clinical trials. The analysis will be carried on the perspective
interdisciplinary on the biomarkers including anatomy, physiology, pharmacology,
biochemistry, history path and development of pharmacy. Particular in-depth
insight may open a window for new researches and lighting the therapies.
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1. Introduction
Advance pancreatic cancer (APC) is a highly lethal tumor. Most patients with
APC remain asymptomatic until the disease reaches an advanced stage [1]. The
incidence rate was 5.5 for men and 4.0 for women per 100,000 people. The mor-
tality rate was 5.1 for men and 3.8 for women per 100,000 people around the world,
according to data, from 2018 [2]. For the incidence rate, Asia is at 48.4%, Europe
at 23.4%, and the Americas is at 21.0%. As for the mortality rate, Asia is at 57.3%,
Europe at 20.3%, and the Americas is at 14.3% [3].
Our previous study disclosed that there were more than 19 chemotherapy regi-
mens combinations in clinical practice available [4]. The advantages and disadvan-
tages of each therapy regimens are clear. Briefly, to lengthen the overall survival
and to reduce the treatment-related toxicity we must consider the outclass selec-
tion. There are more than 14 treatment-related toxicities in gastrointestinal, consti-
tutional, skin, hepatotoxicity, infection, vascular, neuropathy, mental, pain, renal,
electrolytes and pulmonary of human body in current dominant chemotherapy
regimens. To broaden the balance requires expertise and professional medical
training based on evidence.
2. Long period run in research and development in pharmacy
The development of drugs is based on the determination of new therapeutic
targets, the pharmacological receptors. This concept was first proposed by Paul
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Ehrlich in 1908 [5]. Normal cells replicate their DNA with great accuracy, but
cancer has a large number of mutations that show up in cancer cells that make them
pharmacological targets [6]. From the initial concept of molecular targets, drug
targets were discovered and validated, which successful translated the most drugs
into practice [7].
Excellent and reliable targets identification and validation can increase the cred-
ibility of the relationship between intentions and diseases, this may strength the
effectively of drugs. Drugs are usually developed only when specific drug target for
the action of these drugs are analyzed and examined. Sufficient potential targets
have been discovered rapidly for the drug discovery process.
Numerous data including identified gene and drug discovery cycles have been
generated exponentially. This may forge the difficultness in decision making and
becomes more and more difficult for drug R&D. Thanks to rapid bioinformatic
discoveries, more and more biopharmaceutical targets can be identified and
analyzed [8].
Validation from cross-species a bioeffect is performed after the drug target is
determined and verified. Rodents and non-human primates provide appropriate
animal models for screening and evaluation of a new drug. Most of current cancer
in vivo experiments use rodent experimental animals such as mice and rats. Because
they are small, rapid reproduction, clear genetic background and mature genetic
modification technology can be done. However, due to the distant relationship
between rodents and humans, many of the results obtained from rodent models
cannot be reproduced in humans. Moreover, non-human primates are highly simi-
lar to humans in terms of genetic evolution, immunity, physiology and metabolism.
They are theoretically more suitable for cancer researches [9].
Clinical trials are the best channel to tie up pharmaceutical targets to reliable
drugs. The goal is to determine whether a candidate drug is safe and effective. There
are four phases in clinical trials. More specific biomarker studies are based on data
from prospective studies [10]. In the study of cancer biomarkers, retrospective
studies and prospective studies help to identify potential biomarkers, which may
be validated in the future studies, however, the reliability of evidence remains
controversial.
3. Can we trust the current biomarkers of cancer?
Unfortunately, the overall survival of APC patients has not revised assuredly.
There are too many choices in clinical practice and evidence-based medicine is a
permanent challenge. Which of the modern biomarkers is reliable? Are we ever
going to detect precise pharmaceutical targets on APC [11]?
4. Validation method
In order to clarify this question, we collected the raw data source (http://clinica
ltrials.gov) and searched all the drug treatments on APC. We refined all the data
which had results and were published. Briefly, a total of 2726 recordings were found
since May 2019. Hundred and fifteen recordings which finished clinical trials,
further we ruled out irrelevant 32 recordings and 56 unclear results. Finally, 27
recordings kept comprising the following three tables. Raw data are free, please
follow the link 10.6084/m9.figshare.8275190.
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5. What can data tell us?
Total, there are 18 biomarkers used among these results. For details please see
Table 1. The results from 27 clinical trials could be divided into three categories (a)
rank of the effectiveness (b) rank of intervention and (c) quality of life improved.
5.1 Estimation of clinical trials with success outcome on advanced pancreatic
cancer
Total, we found 10 publications where the author declares the successful out-
come on the treatment of APC from 2011 to 2019, Table 2. These clinical trials
recruited 1080 patients with APC (611 male and 469 female). The average overall
survival month is 11.62 and progress-free survival month is 10.79. Briefly, Lutz et al.
tests the GVAX pancreatic cancer vaccine via GPI biomarkers The OS and PFS
approach got the highest point, 24.8 and 17.3, respectively Similarly, Phan et al.
tested the pazopanib hydrochloride via VEGF biomarkers. This approach had a
higher OS and PFS points. Survival months are 25 and 14.4. Furthermore, Hong
et al. disclosed the capecitabine may put the OS and PFS to 17.3 and 10.4 survival
months; the remain studies presented similar results, the OS and PFS were lower
than 10 months.
Biomarkers Abbreviation
Vascular endothelial growth factor* VEGF
Thymidine phosphorylase TP
Epidermal growth factor receptor* EGFR
Tumor necrosis factor α TNF-α
Topoisomerase I inhibitor TIH
Sonic hedgehog SHH
Severe hypoxia intracellular reductases SHIR
Secreted protein acid rich in cysteine SPARC
Platelet-derived growth factor PDGF
MEK1/2-dependent effector proteins ERK1/2
Kirsten rat sarcoma viral oncogene homolog* KRAS
Interleukin 6/interleukin 8 IL-6/IL-8
Heat shock protein 27 Hsp27
Glycosyl-phosphatidylinositol GPI
Double-strand breaks in DNA —
Checkpoint kinase 1 CHK1
Microtubule-associated protein light chain 3- II LC3- II
Circulating free DNA cfDNA
Dihydropyrimidine dehydrogenase DPD
NCCN Recommend: National Comprehensive Cancer Network.
Table 1.
Potential biomarkers used in advanced pancreatic cancer.
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Year Author N M F Drug OS PFS Biomarkers
2011 Hill [12] 21 8 13 Capecitabine;
docetaxel;
7.4 5.8 TP
gemcitabine
2011 Lutz [13] 60 37 23 GVAX pancreatic
cancer
24.8 17.3 GPI
Vaccine
2011 Raymond [14] 86 42 44 Sunitinib 9 30 VEGF
85 40 45 Sunitinib 21 51
2013 Hosein [15] 19 9 10 Abraxane 7.3 1.7 SPARC
2014 Soares [16] 43 21 22 Capecitabine;
docetaxel
5.3 3.7 TP
2014 Ban [17] 33 30 3 Belotaxel; belloxa 10.9 3.6 Double-strand breaks in
DNA
2014 Borad [18] 69 40 29 TH-302 with
gemcitabine;
6.9 3.6 Severe hypoxia
Intracellular reductases
Gemcitabine
71 44 27 TH-303 with
gemcitabine;
8.7 5.6
gemcitabine
74 42 32 TH-304 with
gemcitabine;
9.2 6
gemcitabine
2015 Phan [19] 32 22 10 Pazopanib
hydrochloride
25 14.4 VEGF
20 12 8 Pazopanib
hydrochloride
18.5 12.2
2019 Wang-Gillam
[20]
151 87 64 MM-398 4.9 2.7 Topoisomerase I inhibitor
149 81 68 5 Fluorouracil;
leucovorin
4.2 1.6
117 69 48 MM-398; 5
fluorouracil;
6.2 3.1
leucovorin
Table 2.
Clinical trials with a successful outcome on pancreatic cancer.
Year Author N M F Drug OS PFS Biomarkers
2008 Spano [21] 69 35 34 Gemcitabine 5.6 3.7 VEGF
34 16 18 Gemcitabine; AG-013736 6.9 4.2
2015 Hobday [22] 58 29 29 Bevacizumab; temsirolimus 34 13.2 VEGF
2016 Stein [23] 37 21 16 MPC modified FOLFIRINOX 10.2 6.1 DPD
31 20 11 LAPC modified FOLFIRINOX 26.6 17.8
Table 3.
Clinical trial with neutral outcomes on pancreatic cancer.
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5.2 Estimation of clinical trials with the neutral outcome on advanced
pancreatic cancer
Here are three studies clarified neural results in OS and PFS result, ranged
from 2008 to 2016, totally recruited 229 APC patients (121 male and 108 female).
For details please see Table 3. Averagely the OS is 16.6 months and PFS is
9 months in neutral studies. For example, Jean in 2008 reported gemcitabine
plus AG-013736 achieved better OS and PFS (6.9 and 4.2) than gemcitabine
single used.
5.3 Estimation of clinical trials with the failed outcome on advanced pancreatic
cancer
Regarding the failed outcomes, there are 14 studies ranged from 2011 to 2018,
recruited 2448 APC patients (1385 male and 1063 female) for clinical trials. For
details please see Table 1. Averagely the OS is 8.25 months and PFS is 4.39 months.
It is evident that Faivre et al. in 2016 tested sunitinib malate to treat APC and
achieved 38.6 months of OS and 12.6 months of PFS. However, Brian reported that
hydroxychloroquine cures APC, unfortunately, there were 1.8 months both in OS
and PFS negativity. Even though many combination tests, the benefit for APC
patient is low.
6. Different perspectives on biomarkers
6.1 Vascular endothelial growth factor, VEGF
VEGF is a highly specific vascular endothelial cell mitogen and an angiogenic
factor associated with platelet-derived growth factor (PDGF) structure. It is also
known as vascular permeability factor (VPF), due to its permeabilization of blood
vessels [38]. It is a subfamily of growth factors and belongs to a family of platelet-
derived growth factors of cystine knot growth factor. VEGF is divided into the
following groups: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental
growth factor. VEGF binds to three transmembrane receptors (VEGFR1, VEGFR2
and VEGFR3). This receptor initiates downstream signaling through intracellular
tyrosine kinase activity [39]. In fact, VEGF family members are playing an
important role in the physiological angiogenesis of adults. Like wound healing,
ovulation and pregnancy [40].
Activation of the VEGF/VEGF receptor (VEGFR) axis may trigger multiple
signaling networks. Consequently, this may lead to endothelial cell survival,
mitosis, migration and differentiation, vascular permeability and mobilization of
endothelial progenitor cells (EPCs) from the bone marrow into the peripheral
circulation [41]. On ligand binding, VEGFR-2 dimerization results in kinase activa-
tion and autophosphorylation of tyrosine residues. Activation of PKC may stimulate
the Raf/MEK/ERK pathway, which accelerates the cell proliferation. Ca2+ mobiliza-
tion and PKC activation are playing the key role in signaling events for VEGF-
A-induced vascular permeability through activation of endothelial nitric oxide
synthase activity [42].
The sword has double sides. VEGF participates in the pathogenesis of cancer,
proliferative retinopathy and rheumatoid arthritis [43]. Its antibodies have shown
therapeutic potential to inhibit tumor growth in vivo by inhibiting tumor-induced
angiogenesis [44]. VEGF overexpression is associated with a variety of tumor pro-
gression and poor prognosis, including colorectal cancer [45], pancreatic cancer [46],
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gastric cancer [47], breast cancer [48], lung cancer [49], prostate cancer [50] and
melanoma [51]. This unique protein aids tumors grow and can be used for cancer
treatment if used properly.
Early in 1971, Folkman first proposed the idea of angiogenesis. He believed that
tumor growth and proliferation are closely related to angiogenesis and could be
used as a targeted tumor therapy procedure [52]. Subsequently, countless scientists
gathered in the field of VEGF to study the molecular mechanism of VEGF in tumor
angiogenesis. They have also used it as a drug target to block the formation of blood
vessels, thereby inhibiting tumor growth [53]. Studies have shown that the mecha-
nism of anti-VEGF inhibitors may involve a variety of signaling pathways, such as
FGF, D114, PGF/VEGFR1 and VEGF-C/VEGFR2. At least some of these pathways
can increase the efficacy of VEGF inhibitors [54]. The anti-tumor drugs were
developed with VEGF as the main target area. Like anti-VEGF humanized mono-
clonal antibody, VEGF-targeted antibody, protein kinase inhibitor and tumor vac-
cine [55, 56]. However, in the clinical application of anti-antigenic drugs, reliable
biomarkers have not been found to screen the target population before patient
improvement.
Our data disclosed that there were two studies reporting successful outcomes
[14, 19], two studies reported neutral outcomes [21, 22] and four studies reported
negative outcomes [24–26, 32]. The results from the above eight trials remain
controversial.
Regarding successful outcomes, Raymond et al. found that neuroendocrine
tumors may be particularly sensitive to the combined inhibition of VEGFR and
PDGFR. As for the neutral outcomes [14], Spano et al. used the gemcitabine +
axitinib to treat the APC [21]. However, results differ from the results of Phase III
trials in which erlotinib + gemcitabine confers the greatest survival advantage for
patients with ECOG status 2 and metastatic disease, it possibly due to the mecha-
nism of action between different EGFR and VEGFR inhibitors. Moreover, Hobday
et al. found that the median PFS in the gefitinib trial was only 3.7 months which was
even lower than the placebo group in the phase III trial [22].
With respect to the failed outcomes, Kindler et al. found that the effect of
axitinib and gemcitabine on APC was limited to improve the survival period in
patients with locally APC [24]. In fact, the results may be related to the gene locus
of the VEGF receptor 1 tyrosine kinase domain. Furthermore, Ropugier et al. found
that PFS was not significantly improved between the treatment arms. It indicates
that blocking the VEGF/VEGFR axis does not lead to the survival of a patient with
APC [26]. Nooan et al. study shows that pelareorep combination chemotherapy is
not a sufficient solution to overcome the severe immunosuppression prevalent in
PCA patients [32].
6.2 Epidermal growth factor receptor, EGFR
EGFR is one of the transmembrane receptors of epidermal growth factor family
members of extracellular protein ligands. Its main function is to regulate various
cellular functions including proliferation, movement and differentiation. Its mech-
anism can be described as the binding of the ligand to EGFR leading to dimerization
followed by autophosphorylation of EGFR and activation of downstream signaling
pathways. Activation of EGFR triggers multiple signal cascades within the cell,
ultimately leading to gene transcription and biological responses [57]. Recently,
studies have shown that dimerization occurs even in the absence of ligands, partic-
ularly when EGFR is overexpressed, possibly limited to a subset of dimers. More-
over, overexpressed EGFR can dimerize and become tyrosine phosphorylated
without ligand [58].
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EGFR signal transduction pathway can directly participate in tumor pathogene-
sis and progression [59]. EGFR overexpression plays a major role in carcinogenesis
in cancer development [60]. Overexpression of EGFR accounts for 90% in pancre-
atic cancer cells [61]. Specifically, the aberrant activity of EGFR may impact the
development and growth of tumor cells [62].
Mutation of EGFR may induce the resistance of tyrosine kinase inhibitors (TKIs)
[63]. Notably, in tumor angiogenesis, vascular endothelial growth factor receptor-2
(VEGFR-2) plays a key role, and inhibition of VEGFR-2 signaling pathway has
become an attractive cancer treatment method [64]. The binding of VEGF to
VEGFR-2 stimulates the signaling pathway (PI3K/Akt, p38MAPK) that mediates
several cellular functions. Besides, glycoproteins, EGFR and VEGFR-2 are in close
correlation. Inhibition of EGFR can also reduce VEGF expression, while VEGFR-2
targeting can enhance the anticancer activity of EGFR inhibitors. Therefore, the
dual inhibition treatment of EGFR and VEGFR-2 has a good effect and represents a
promising cancer treatment. Recently, several EGFR/VEGFR-2 dual inhibitors have
been discovered, such as vandetanib showing effective inhibitory activity on EGFR
and VEGFR-2 [65].
A receptor tyrosine kinase is associated with cell proliferation and survival.
Epidermal Growth Factor Receptor, EGFR, is overactive in many epithelial-derived
tumors. It has been reported that EGFR is not related to its kinase activity, but
rather maintains basal intracellular glucose levels to prevent autophagic death of
cells. Despite the presence of chemotherapeutic drugs and tyrosine kinase inhibi-
tors, this function of EGFR allows tumor cells to have higher viability [66]. EGFR
inhibitors for cancer therapy are rapidly evolving in the broad context of cancer
therapy, and in those patients achieving significant tumor response to EGFR inhib-
itors. Most patients will eventually exhibit disease progression, suggesting
acquired resistance. This reminds us that increasing our ability to recognize tumors
that depend on EGFR signaling growth is critical for the best choice of treating
patients [67].
Unfortunately, two clinical trials showed that the results failed via EGFR. Stud-
ies by Ko et al. showed that subjects treated by cetuximab, bevacizumab and
gemcitabine had 5.41 months in OS and 4.17 months in PFS. Propper et al. in 2014
tested Erlotinib to treat APC, and only achieved 4.0 months of OS and 1.5 months of
PFS, Table 4 [25, 28]. Ko reported the incidence of severe (grades 3–5) toxicity,
comparable to the use of gemcitabine as a single agent in this patient population
which may reflect a relatively short duration of treatment due to lack of efficacy.
Moreover, it is difficult to explain the quality of life analysis based on the number of
patients completing the series of questionnaires and the overall time the patients
stayed in the study [25]. Propper concluded that there is limited evidence to support
the use of predictive biomarkers for patients with pancreatic cancer who could
benefit from targeted therapies [28].
6.3 Kirsten rat sarcoma viral oncogene homolog, KRAS
KRAS protein plays a key role in human cancer but has not yet succumbed to
therapeutic attacks [68]. The search is now focused on targeting alternative
pathways that are activated in mtKRAS cells, to circumvent or prevent drug
resistance [69].
There are currently no therapeutic interventions for KRAS. Pharmacological
agents that are speculated to inhibit KRAS include farnesyltransferase inhibitors
that block the binding of KRAS to the cell membrane. These drugs have failed in
clinical studies. Antisense oligonucleotides and engineered microRNAs (miRNAs)
have been used as an alternative to targeted mutations in KRAS without disrupting
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the expression of non-mutant KRAS and have achieved some success in preclinical
trials [70].
In recent years, many studies have suggested that the oncogene KRAS plays a
major role in controlling cancer metabolism by coordinating multiple metabolic
changes [71]. Furthermore, combined inhibition of therapeutic effects and feedback
pathways is promising in KRAS mutant cancers. Moreover, it is unclear what spe-
cific pathways should be used to optimize treatment response [72].
Year Author N M F Drug OS PFS Biomarkers
2011 Kindler [24] 314 191 123 Gemcitabine; AG-013736 8.5 4.4 VEGF
316 188 128 Gemcitabine; placebo 8.3 4.4
2012 Ko [25] 29 18 11 Cetuximab; bevacizumab
gemcitabine
5.41 4.17 EGFR
VEGF
29 14 15 Cetuximab; bevacizumab 3.55 1.91
2013 Rougier [26] 275 157 118 Placebo; gemcitabine 7.8 3.7 VEGF
271 160 111 Aflibercept; gemcitabine 6.5 3.7
2013 Wu [27] 30 16 14 Etanercept; gemcitabine 5.43 0.3 TNF-α
8 3 5 Gemcitabine 8.1 1.8
2014 Propper [28] 104 59 45 Erlotinib 4.0 1.5 EGFR
103 59 44 Placebo 3.1 1.5
2014 Infante [29] 80 39 41 Gemcitabine; GSK1120212 8.4 16.1 cfDNA
80 46 34 Placebo; gemcitabine 6.7 15.1
2014 Wolpin [30] 10 5 5 Hydroxychloroquine 400 mg 1.8 1.8 LC3-II
10 6 4 Hydroxychloroquine 600 mg 3.0 1.6
2015 Catenacci [31] 53 27 26 Gemcitabine hydrochloride;
Placebo
6.1 2.5 SHH
53 31 22 Gemcitabine hydrochloride;
vismodegib
6.9 4.0
2016 Noonan [32] 36 22 14 wild-type reovirus; carboplatin;
paclitaxel
7.31 4.94 VEGF;
IL-6;
IL-8
37 19 18 Carboplatin; paclitaxel 8.77 5.2
2017 Chung [33] 62 22 40 Fluorouracil; oxaliplatin 6.7 2.0 KRAS
protein
58 35 23 Akt inhibitor
MK2206; selumetinib
3.9 1.9
2017 Faivre [34] 86 42 44 Sunitinib malate 38.6 12.6 VEGF;
PDGF
85 40 45 Placebo 29.1 5.8
2017 Ko [35] 66 38 28 OGX-427 6.9 3.8 Hsp27
66 37 29 Placebo 5.3 2.7
2017 Laquente [36] 65 42 23 LY2603618; gemcitabine 7.8 3.5 CHK1
34 20 14 Gemcitabine 8.3 5.6
2018 Van Cutsem
[37]
44 22 22 Gemcitabine; placebo 7.6 2.8 ERK 1/2
44 27 17 Gemcitabine; pimasertib 7.3 3.7
Table 4.
Clinical trial failed outcome on pancreatic cancer.
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Unfortunately, Chung et al. tested pharmaceutical target via KRAS protein,
whereas the result was unsuccessful. The results showed that the OS and PFS of
patients treated by Akt Inhibitor MK2206 and selumetinib were 3.9 and 1.9 months,
respectively, see Table 4 [33]. The results indicated that the strategy of utilizing
two or more kinase inhibitors is subject to the challenge of toxicity overlap. These
toxicities will significantly block the delivery of effective inhibitory amounts of
both drugs in vivo. However, a major disadvantage factor is the delay in toxicity-
related treatment and the frequency of dose reduction in the experimental group
through damaging sustained signal suppression [33].
7. Conclusion
APC reserves unpredictable mechanisms to maintain a highly resistant pheno-
type. The genetic and epigenetic alterations of the APC lead to the resistance of the
chemotherapy.
Nowadays, many biomarkers have been on board to improve the clinical treat-
ment outcome of advanced pancreatic cancer. Although these successful bio-
markers have provided notable therapeutic effects on advanced pancreatic cancer,
the outcomes remain unsatisfactory to the patients and health providers. With the
development of the biology of advanced pancreatic cancer, we now expect better
biomarkers and conduct therapy by unveiling the tumor microenvironment and the
mechanism of the mutations (Figure 1).
We can assume that with the development of truly effective treatments and
clinically useful markers for early detection of the disease, better combination of
markers to advanced pancreatic cancer. In the meanwhile, researchers are trying to
detect magnificently predictive biomarkers to decide the treatment strategy and
permit practitioners to adequately evaluate and propose individualized treatment
protocols which would give a greater survival rate.
Clearly, there is a need to better understand the underlying signaling networks
that drive pancreatic cancer progression and potential escape mechanisms. In addi-
tion, it is necessary to improve the role of preclinical models of pancreatic cancer
Figure 1.
Difficulties in decision making both for R&D and doctors.
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and the optimal transformation of preclinical success into experimental design. The
genetic and proteomic technologies show great potential to detect the novel bio-
markers in cancer research. We place great expectations on these technologies to
personalize treatment for advanced pancreatic cancer patients.
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